$ABUS SEC Filings

Filed On	Filing
27 Oct 2026	SCHEDULE 13G/A
22 Oct 2026	8-K: Other Events WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the Company was ...
07 Oct 2026	Form 4: Beardsley Robert A, Director Returned 17,948 shares to the issuer ($89.7K)
07 Oct 2026	Form 4: Nguyen Tuan, Chief Financial Officer Returned 48,081 shares to the issuer ($240K)
07 Oct 2026	Form 4: Sawhney Roger, Director Returned 17,142 shares to the issuer ($85.7K)
07 Oct 2026	Form 4: Androski Lindsay, Director Returned 24,655 shares to the issuer ($123K)
07 Oct 2026	SCHEDULE 13G/A
05 Oct 2026	Form 4: Roivant Sciences Ltd., Director Returned 8,967,383 shares to the issuer ($44.8M)
05 Oct 2026	SCHEDULE 13D/A
01 Oct 2026	SC TO-I/A
30 Sep 2026	SC TO-I/A
23 Sep 2026	Form 4: Androski Lindsay, Director Received 126,864 shares by exercise or conversion ($418K) · Gave up 82,527 shares to cover exercise price or tax ($418K)
23 Sep 2026	Form 4: Nguyen Tuan, Chief Financial Officer Received 293,100 shares by exercise or conversion ($1.05M) · Gave up 206,637 shares to cover exercise price or tax ($1.05M)
23 Sep 2026	Form 4: Sawhney Roger, Director Received 131,333 shares by exercise or conversion ($510K) · Gave up 100,508 shares to cover exercise price or tax ($510K)
23 Sep 2026	Form 4: Beardsley Robert A, Director Received 131,333 shares by exercise or conversion ($502K) · Gave up 99,057 shares to cover exercise price or tax ($502K)
04 Sep 2026	SCHEDULE 13G
24 Aug 2026	SC TO-I
21 Aug 2026	SC TO-C
21 Aug 2026	8-K: Other Events
12 Aug 2026	SCHEDULE 13G/A

Comments